Literature DB >> 18419361

Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE.

Chamion N Olivier1, Ruth K Blake, Lisa L Steed, Cassandra D Salgado.   

Abstract

BACKGROUND: Colonization with vancomycin-resistant Enterococcus (VRE) is a risk factor for subsequent VRE bloodstream infection (BSI); however, risk factors for BSI among colonized patients have not been adequately described. We sought to determine the proportion of VRE-colonized patients who subsequently develop VRE BSI and to identify risk factors for VRE BSI among these patients.
METHODS: Records of 768 patients colonized with VRE from January 2002 through June 2005 were reviewed. The proportion of patients who developed VRE BSI was calculated, and the characteristics of these patients were compared, in a 2:1 ratio, with those of patients who did not develop VRE BSI. To identify risk factors for VRE BSI and for death, we used univariate logistic regression analysis and then multivariate logistic regression analysis. Using pulsed-field gel electrophoresis (PFGE), we compared the isolate recovered when the patient was colonized and the isolate recovered when the patient developed VRE BSI.
RESULTS: Of the 768 patients colonized with VRE, 31 (4.0%) developed VRE BSI. Multivariate analysis identified the following independent risk factors for developing VRE BSI: infection of an additional body site other than blood (adjusted odds ratio [aOR], 3.9; P = .04), admission to the hospital from a long-term care facility (aOR, 12.6; P = .04), and receipt of vancomycin (aOR, 10.6; P = .001). The independent risk factors for death among patients colonized with VRE were immunosuppression (aOR, 12.9; P = .001) and VRE BSI (aOR, 9.1; P = .002). Of the 31 patients who developed VRE BSI, 23 (74%) had a pair of isolates representing VRE colonization and VRE BSI. For 19 (83%) of these 23 patients, the isolate representing BSI was genetically related to the isolate representing VRE colonization: 12 pairs of isolates (52%) had identical banding patterns, 5 had closely related patterns, and 2 had possibly related patterns.
CONCLUSION: Of the 768 patients colonized with VRE, 31 (4.0%) usually developed VRE BSI due to a related strain. Independent risk factors for BSI among colonized patients were admission from a long-term care facility, infection of an additional body site, and exposure to vancomycin. Independent risk factors for death were immunosuppression and VRE BSI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419361     DOI: 10.1086/587647

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  29 in total

1.  Vancomycin-resistant enterococci colonization in patients with hematological malignancies: screening and its cost-effectiveness.

Authors:  Habip Gedik; Funda Şimşek; Arzu Kantürk; Taner Yıldırmak; Deniz Arıca; Demet Aydın; Osman Yokuş; Naciye Demirel
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 3.  Diagnostic challenges and opportunities in older adults with infectious diseases.

Authors:  David van Duin
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

4.  Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation.

Authors:  M Tavadze; L Rybicki; S Mossad; R Avery; M Yurch; B Pohlman; H Duong; R Dean; B Hill; S Andresen; R Hanna; N Majhail; E Copelan; B Bolwell; M Kalaycio; R Sobecks
Journal:  Bone Marrow Transplant       Date:  2014-08-11       Impact factor: 5.483

5.  Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Authors:  Daniela Jabés; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

6.  Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE.

Authors:  John B Bossaer; Philip D Hall; Elizabeth Garrett-Mayer
Journal:  Support Care Cancer       Date:  2010-01-13       Impact factor: 3.603

7.  Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.

Authors:  Yao-Wen Cheng; Emmalee Phelps; Vincent Ganapini; Noor Khan; Fangqian Ouyang; Huiping Xu; Sahil Khanna; Raseen Tariq; Rachel J Friedman-Moraco; Michael H Woodworth; Tanvi Dhere; Colleen S Kraft; Dina Kao; Justin Smith; Lien Le; Najwa El-Nachef; Nirmal Kaur; Sree Kowsika; Adam Ehrlich; Michael Smith; Nasia Safdar; Elizabeth Ann Misch; Jessica R Allegretti; Ann Flynn; Zain Kassam; Asif Sharfuddin; Raj Vuppalanchi; Monika Fischer
Journal:  Am J Transplant       Date:  2018-08-31       Impact factor: 8.086

8.  The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms.

Authors:  Srinivasa Nithin Gopalsamy; Michael H Woodworth; Tiffany Wang; Cynthia T Carpentieri; Nirja Mehta; Rachel J Friedman-Moraco; Aneesh K Mehta; Christian P Larsen; Colleen S Kraft
Journal:  Am J Med Sci       Date:  2018-08-29       Impact factor: 2.378

9.  Evaluation of vancomycin resistance 3 multiplexed PCR assay for detection of vancomycin-resistant enterococci from rectal swabs.

Authors:  Yesim Cekin; Aylin Erman Daloğlu; Dilara Oğünç; Betil Ozhak Baysan; Duygu Dağlar; Dilara Inan; Derya Mutlu; Gözde Ongüt; Dilek Colak
Journal:  Ann Lab Med       Date:  2013-08-08       Impact factor: 3.464

10.  Sequence type 17 is a predictor of subsequent bacteremia in vancomycin-resistant Enterococcus faecium-colonized patients: a retrospective cohort study.

Authors:  Si-Ho Kim; Sun Young Cho; Hye Mee Kim; Kyungmin Huh; Cheol-In Kang; Kyong Ran Peck; Doo Ryeon Chung
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-22       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.